HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Targets Supplement Firm In Administrative Proceeding After Contempt Complaint Fails

Federal Judge Says Settlement Stipulation Against ‘Treats Disease’ Claims Is Ambiguous

Executive Summary

A ruling in Maine federal court questions whether FTC could show firms made claims a product labeled as a supplement “cures, mitigates, or treats any disease." But agency's administrative complaint includes the same phrase as a stipulation among the penalties it would order.

You may also be interested in...



Arizona Cannabinoid Supplement Firm Agrees To Stop After Acknowledging 34 False Claims

Arizona CBD marketer Kushly Industries is ordered to no longer make disease claims for products without competent and reliable scientific evidence. Settlement lists 16 examples of claims but order in US district court identifies 32 claims the firm acknowledged it used in advertising.

Supplement Firms Launch New Brands, But Charged With Same Violations By FTC

Firms allegedly made false claims for four products labeled as supplements they launched since 2018 settlement. “Brazenly ignoring the Court’s order barring them from making unsubstantiated claims,” firms “have continued promoting their products with outrageous claims,” FTC contends.

Align Supplement Industry Regulation With DSHEA, Groups Tell FDA In 'Responsible Innovation' Comments

Targeted guidance on questions around NDINs and using import alerts to keep violative products off market are among supplement industry trade groups' suggestions for improving FDA oversight of the industry. Groups also continue asserting that the agency can strengthen its VMS product manufacturing and marketing oversight with its existing authorities.

Related Content

Topics

UsernamePublicRestriction

Register

RS150726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel